Core Viewpoint - Tianyuan Medical (00557) announced a capital increase agreement involving its indirect subsidiaries, which aims to enhance the operational capacity of Shanghai Rifu and strengthen the group's competitiveness in the medical services sector in China [1][3]. Group 1: Capital Increase Agreement - Hengqin Hanyue Mei will increase its investment in Shanghai Rifu by RMB 15.5152 million (approximately HKD 16.9116 million) through the conversion of debt into equity [1]. - Shanghai Huaman will contribute an additional RMB 10 million (approximately HKD 10.9 million) in cash to Shanghai Rifu [1]. - Following the capital increase, Shanghai Rifu's registered capital will rise from RMB 2.3846 million to RMB 27.8998 million, while the shareholding ratios of Hengqin Hanyue Mei and Shanghai Huaman will remain unchanged at 60.8077% and 39.1923%, respectively [1]. Group 2: Shareholder Loan Agreement - On July 21, 2025, Shanghai Huaman will provide a shareholder loan of RMB 3 million (approximately HKD 3.27 million) to Shanghai Rifu, with a loan term of 36 months [1]. Group 3: Strategic Collaboration - The capital increase and shareholder loan are designed to meet the operational funding needs of Shanghai Rifu, thereby providing additional working capital for its daily operations [3]. - The collaboration with Shanghai Huaman, a marketing company in the medical beauty sector, is expected to enhance the group's strategic value and create potential cooperation opportunities with other medical beauty centers in China [3]. - This partnership is anticipated to bring further support and resources to Shanghai Rifu and the overall group, driving growth momentum [3].
天元医疗(00557)：横琴韩悦美及上海日复拟向上海日复增资